Cancer Genetics and Epigenetics, 2025, Vol.13, No.6, 300-309 http://medscipublisher.com/index.php/cge 309 Motzer R.J., Tannir N.M., McDermott D.F., Arén Frontera O., Melichar B., Choueiri T.K., Plimack E.R., Barthélémy P., Porta C., George S., Powles T., Donskov F., Neiman V., Kollmannsberger C.K., Salman P., Gurney H., Hawkins R., Ravaud A., Grimm M.O., Bracarda S., Barrios C.H., Tomita Y., Castellano D., Rini B.I., Chen A.C., Mekan S., McHenry M.B., Wind-Rotolo M., Doan J., Sharma P., Hammers H.J., and Escudier B., 2018., Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, New England Journal of Medicine, 378(14): 1277-1290. https://doi.org/10.1056/NEJMoa1712126 Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F., Thompson J.A., and Obeid M., 2019, Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance, Nature Reviews Clinical Oncology, 16(9): 563-580. https://doi.org/10.1038/s41571-019-0218-0 Rini B.I., Plimack E.R., Stus V., Gafanov R., Hawkins R., Nosov D., Pouliot F., Alekseev B., Soulières D., Melichar B., Vynnychenko I., Kryzhanivska A., Bondarenko I., Azevedo S.J., Borchiellini D., Szczylik C., Markus M., McDermott R.S., Bedke J., Tartas S., Chang Y.H., Tamada S., Shou Q., Perini R.F., Chen M., Atkins M.B., and Powles T., 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, New England Journal of Medicine, 380(12): 1116-1127. https://doi.org/10.1056/NEJMoa1816714 Routy B., Le Chatelier E., Derosa L., Duong C.P.M., Alou M.T., Daillère R., Fluckiger A., Messaoudene M., Rauber C., Roberti M.P., Fidelle M., Flament C., Poirier-Colame V., Opolon P., Klein C., Iribarren K., Mondragón L., Jacquelot N., Qu B., Ferrere G., Clémenson C., Mezquita L., Masip J.R., Naltet C., Brosseau S., Kaderbhai C., Richard C., Rizvi H., Levenez F., Galleron N., Quinquis B., Pons N., Ryffel B., Minard-Colin V., Gonin P., Soria J.C., Deutsch E., Loriot Y., Ghiringhelli F., Zalcman G., Goldwasser F., Escudier B., Hellmann M.D., Eggermont A., Raoult D., Albiges L., Kroemer G., and Zitvogel L., 2018, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, 359(6371): 91-97. Schmid P., Adams S., Rugo H.S., Schneeweiss A., Barrios C.H., Iwata H., Diéras V., Hegg R., Im S.A., Shaw Wright G., Henschel V., Molinero L., Chui S.Y., Funke R., Husain A., Winer E.P., Loi S., and Emens L.A., 2018, Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, New England Journal of Medicine, 379(22): 2108-2121. https://doi.org/10.1056/NEJMoa1809615 Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Finley G., Kelsch C., Lee A., Coleman S., Deng Y., Shen Y., Kowanetz M., Lopez-Chavez A., Sandler A., and Reck M., 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, New England Journal of Medicine, 378(24): 2288-2301. https://doi.org/10.1056/NEJMoa1716948 Tawbi H.A., Schadendorf D., Lipson E.J., Ascierto P.A., Matamala L., Castillo Gutiérrez E., Rutkowski P., Gogas H.J., Lao C.D., De Menezes J.J., Dalle S., Arance A., Grob J.J., Srivastava S., Abaskharoun M., Hamilton M., Keidel S., Simonsen K.L., Sobiesk A.M., Li B., Hodi F.S., and Long G.V., 2022, Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma, New England Journal of Medicine, 386(1): 24-34. https://doi.org/10.1056/NEJMoa2109970 Theelen W.S.M.E., Peulen H.M.U., Lalezari F., van der Noort V., de Vries J.F., Aerts J.G.JV., Dumoulin D.W., Bahce I., Niemeijer A.N., de Langen A.J., Monkhorst K., and Baas P., 2019, Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer, JAMA Oncology, 5(9): 1276-1282. https://doi.org/10.1001/jamaoncol.2019.1478 Wang D.Y., Salem J.E., Cohen J.V., Chandra S., Menzer C., Ye F., Zhao S., Das S., Beckermann K.E., Ha L., Rathmell W.K., Ancell K.K., Balko J.M., Bowman C., Davis E.J., Chism D.D., Horn L., Long G.V., Carlino M.S., Lebrun-Vignes B., Eroglu Z., Hassel J.C., Menzies A.M., Sosman J.A., Sullivan R.J., Moslehi J.J., and Johnson D.B., 2018, Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis, JAMA Oncology, 4(12): 1721-1728. https://doi.org/10.1001/jamaoncol.2018.3923
RkJQdWJsaXNoZXIy MjQ4ODYzNA==